The table above outlines our assumptions that by initiating strategy development independently and in parallel with an ex-Japan Phase I trial, companies can accelerate their development timeline by two years. IDA assists companies in obtaining optimal licensing terms by first helping to create a more concrete and convincing story regarding a product's value in Japan, and then by empowering them to independently maintain a compound's development momentum and progress towards the Japanese market.
